“Biote’s third quarter revenue increased 12.8% from the prior-quarter period, driven by continued growth in procedure revenue and a strong return to growth in our dietary supplements business,” said ...
IRVING, Texas--(BUSINESS WIRE)--Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today ...
Reports Q4 revenue $49.8M, consensus $51.2M. “In 2024 Biote (BTMD) strengthened its capabilities to provide the next level of individualized and evidence-based healthcare,” said Bob Peterson, Biote ...
Peterson stated, "we reiterate our fiscal 2025 revenue guidance of above $190 million and our fiscal 2025 adjusted EBITDA guidance of above $50 million." Management continues to expect mid-teens ...
biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today ...
Biote Corp. ( (BTMD)) has released its Q2 earnings. Here is a breakdown of the information Biote Corp. presented to its investors. Take advantage of TipRanks Premium at 50% off! Unlock powerful ...
IRVING, Texas--(BUSINESS WIRE)-- BioTE Holdings, LLC, (Biote), a high-growth, differentiated medical practice-building business within the hormone optimization space ...
Terry Weber: So the primary growth in that procedure, that 6.6% year-over-year procedure growth is in our existing clinics. And I would say there are two categories. One is that top tier clinic. We ...
IRVING, Texas--(BUSINESS WIRE)--Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback